个人简介：

教育经历：

2006.9-2010.7 沈阳药科大学， 药物制剂，学士

2010.8-2016.5 美国堪萨斯州立大学，微生物，博士

工作经历：

2016.6-2017.6 美国堪萨斯州立大学，博士后

2017.7-2018.1 美国洛克菲勒大学，博士后

2018.1-2020.12 美国国立卫生研究院（NIH）免疫与传染病研究所（NIAID）,博士后

研究领域：

主要致力于研究痘病毒（POXVIRUS）的基础病毒学，分子生物学，以及病毒拮抗宿主天然免疫反应的分子机制。 

代表性文章：

Peng, C., and Moss B., Repair of a newly identified host range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells. Proceedings of the National Academy of Sciences of USA. 2019    IF = 9.58

Peng, C., Wyatt, LS., Glushakow-Smith SG., Lal-Nag, M., Weisberg, AS., Moss, B., Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells. PloS Pathogens. 2020    IF 6.463

Peng, C., Zhou, Y., Cao, S., Pant, A., Campos Guerrero ML., et al. Identification of vaccinia virus inhibitors and cellular functions necessary for efficient viral replication by screening bioactive and FDA-approved drugs. Vaccines, 2020.

Peng, C., Haller, S., Rahman, M., McFadden, G. and Rothenburg, S., Myxoma virus M156 is a specific inhibitor of rabbit PKR but contains a loss-of-function mutation in Australian virus isolates. Proceedings of the National Academy of Sciences of USA. 2016  IF = 9.58

Park, C., Peng, C., Rahman, MJ., Haller, SL., Tazi, L., Brennan, G., Rothenburg, S., Orthopoxvirus K3 orthologs show virus- and host-specific inhibition of the antiviral protein kinase PKR. PloS Pathogens. 2021 IF 6.463

Pant, A., Dsouza, L., Cao, S., Peng, C., Yang, Z., Viral growth factor and STAT3 signaling- dependent elevation of the TCA cycle intermediate levels during vaccinia virus infection.PloS Pathogens. 2021 IF 6.463